Brian Mann

McKinsey & Company has reached a $573 million settlement with nearly 50 state governments as well as the District of Columbia and territories, over its role helping to market and boost sales of high-risk opioids including OxyContin.

Most of the funds will be devoted to paying for treatment and rehabilitation programs in communities devastated by the addiction crisis. As part of the settlement, McKinsey admits to no wrongdoing.

This deal heads off civil lawsuits threatened by state attorneys general.

In the weeks after winning the November election, Joe Biden began naming officials to tackle the vortex of crises his administration would face on day one.

The Trump administration introduced new addiction treatment guidelines Thursday that give physicians more flexibility to prescribe a drug to patients struggling with opioid addiction.

For the first time, a medication regime has been found effective for some patients with meth addiction in a large, placebo-controlled trial.

It's welcome news for those working with the growing number of people struggling with meth addiction.

"It's progress and it's quite significant," says Dr. Nora Volkow, director of the National Institute on Drug Addiction, which funded the two-year clinical trial involving roughly 400 patients.

When Ashwani Sheoran showed up for early morning shifts at pharmacies in rural Michigan wearing his white Walmart smock, he often found customers waiting, desperate for bottles of pain pills.

"I see my patients, 15 to 20, already lined up to get prescriptions filled for morphine sulfate, oxycodone and other straight narcotics," he said.

This was in 2012 when the prescription opioid epidemic was exploding, killing tens of thousands of Americans every year.

Pages